| Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension. | |
| | |
MedLine Citation:
|
PMID: 19626403 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Angiotensin II receptor blockers (ARBs) are suggested to be protective against myocardial hypertrophy and fibrosis, although such beneficial effects remain to be elucidated in the human heart. The aim of the present study was to examine the effect of a novel ARB, olmesartan, on myocardial function of the left ventricle in patients with mildto-moderate hypertension. We investigated 10 patients (6 men and 4 women, 62 +/- 7 years of age) who were stable with a single regimen of amlodipine, which was switched to olmesartan. Before and 8 months after changing medications, patients underwent echocardiographic examination and blood sampling, including measurement of the plasma high-sensitivity C-reactive protein (hsCRP) level. Peak velocities at the mitral annulus were determined by tissue Doppler imaging and used as measures of myocardial function. Olmesartan did not significantly alter blood pressure (BP) (systolic BP, 122 +/- 12 to 121 +/- 8 mmHg, P = 0.9; diastolic BP, 79 +/- 6 to 75 +/- 4 mmHg, P = 0.06) or parameters of global left ventricular systolic and diastolic function. Tissue Doppler imaging, however, revealed significant increases in the systolic (8.2 +/- 1.3 to 8.9 +/- 1.1 cm/s, P < 0.01) and early diastolic (6.7 +/- 0.9 to 7.6 +/- 1.0 cm/s, P = 0.02) velocities at the mitral annulus. This was associated with decreases in the left ventricular mass index (83 +/- 15 to 73 +/- 19 g/m2, P = 0.09) and hsCRP (683 +/- 555 to 655 +/- 450 ng/ml, P = 0.07). In conclusion, olmesartan improves myocardial function independent of BP reduction in hypertensive patients. Attenuated inflammatory changes as well as myocardial hypertrophy may play an important role. |
| | |
Authors:
|
Rie Futai; Takahide Ito; Yasunori Kawanishi; Fumio Terasaki; Yasushi Kitaura |
Related Documents
:
|
6704263 - Interaction between systolic and diastolic time intervals in atrial fibrillation. 9397313 - Influence of left ventricular diastole on left atrial appendage blood flow in patients ... 15111193 - Transesophageal echocardiography-guided chordal replacement for tricuspid regurgitation. |
Publication Detail:
|
Type: Clinical Trial; Journal Article Date: 2009-07-22 |
Journal Detail:
|
Title: Heart and vessels Volume: 24 ISSN: 1615-2573 ISO Abbreviation: Heart Vessels Publication Date: 2009 Jul |
Date Detail:
|
Created Date: 2009-07-23 Completed Date: 2009-10-08 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8511258 Medline TA: Heart Vessels Country: Japan |
Other Details:
|
Languages: eng Pagination: 294-300 Citation Subset: IM |
Affiliation:
|
Third Department of Internal Medicine, Osaka Medical College, 2-7 Daigaku-cho, Takatsuki, Osaka 569-8686, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Amlodipine / therapeutic use Angiotensin II Type 1 Receptor Blockers / therapeutic use* Biological Markers / blood Blood Pressure / drug effects* C-Reactive Protein / metabolism Calcium Channel Blockers / therapeutic use Echocardiography, Doppler, Color Female Fibrosis Humans Hypertension / drug therapy*, physiopathology, ultrasonography Hypertrophy, Left Ventricular / drug therapy*, physiopathology, ultrasonography Imidazoles / therapeutic use* Inflammation / drug therapy, physiopathology Male Middle Aged Myocardium / pathology Severity of Illness Index Tetrazoles / therapeutic use* Time Factors Treatment Outcome Ventricular Function, Left / drug effects* |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin II Type 1 Receptor Blockers; 0/Biological Markers; 0/Calcium Channel Blockers; 0/Imidazoles; 0/Tetrazoles; 0/olmesartan; 88150-42-9/Amlodipine; 9007-41-4/C-Reactive Protein |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Treatment strategy and clinical outcome in Japanese patients with atrial fibrillation.
Next Document: Influence of T-calcium channel blocker treatment on deterioration of renal function in chronic kidne...